|

Troriluzole Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: 2-Amino-N-({methyl-[(6-trifluoromethoxy-benzothiazol-2-ylcarbamoyl)-methyl]-carbamoyl}-methyl)-acetamide monohydrate monohydrochloride, BHV-4157, C15H16F3N5O4S.HCl.H2O, FC-4157, Trigriluzole

Pipeline

Early 1: 1Phase 2/3: 1

Top Sponsors

  • Ugonma Chukwueke1
  • Global Coalition for Adaptive Research1

Indications

  • Glioblastoma2
  • Cancer2
  • Recurrent Glioblastoma1
  • Brain Tumor1

Birmingham, Alabama1 trial

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

University of Alabama at Birmingham

Phase 2/3

Boston, Massachusetts1 trial

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

Brigham and Women's Hospital

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.